Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

88 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-05-31

Study Completion Date

2004-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety (including tolerability), pharmacokinetics, pharmacodynamics and clinical activity of BSYX-A110 administered in a 3-dose regimen on Study Days 0, 7, and 14.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110

NCT00631878

Neonatal Staphylococcal Sepsis

COMPLETED PHASE1/PHASE2

Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

NCT00646399

Staphylococcal Sepsis

COMPLETED PHASE2/PHASE3

Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants

NCT00636285

Staphylococcal Sepsis

COMPLETED PHASE1

Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates

NCT00873327

Sepsis

COMPLETED PHASE1

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

NCT04126031

Gram-negative Bacterial Infection

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Phase II study will be a randomized, double blind, placebo controlled study of BSYX-A110 in very low birth weight neonates. A total of 80 infants will be dosed in this study. Participants will receive either BSYX-A110 or placebo, at 60 mg/kg or 90 mg/kg. The Study Drug will be administered at 48-120 hours of life, 7 days after the initial dose, and 14 days after the initial dose for all dose groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Staphylococcal Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Pagibaximab (formerly BSYX-A110)

Intervention Type DRUG

Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14

60 mg/kg

60 mg/kg was given on Days 0, 7, 14

Group Type EXPERIMENTAL

Pagibaximab (formerly BSYX-A110)

Intervention Type DRUG

Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14

90 mg/kg

90 mg/kg was given on Days 0, 7, 14

Group Type EXPERIMENTAL

Pagibaximab (formerly BSYX-A110)

Intervention Type DRUG

Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pagibaximab (formerly BSYX-A110)

Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BSYX-A110 HU96-110 Pagibaximab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients must meet all of the following criteria at the time of first infusion (Day 0):

1. 48-120 hours of age, inclusive
2. Birth weight of 700-1300 grams
3. Inpatient in a Neonatal Intensive Care Unit
4. Written informed consent obtained from the parent(s) or legal guardian

Multiple gestations:

1. Siblings from multiple gestations may be enrolled if they each meet the entry criteria
2. No more than 4 subjects in any birth weight cohort may be siblings

Exclusion Criteria

Patients may have none of the following at the first dose:

1. Survival not expected for at least 1 week after infusion
2. Clinically overt systemic infection, as determined by history, physical examination, and positive culture from a normally sterile site. (Infuse only when infant clinically stable and cultures negative for 48 hours. If being evaluated for sepsis, decision to infuse may be deferred as allowed by protocol infusion window. Infusions outside of protocol window must be approved by Sponsor.)
3. Severe congenital anomalies or genetic disorders that are likely to be fatal or that may interfere with drug distribution or metabolism, as determined by history and/or physical examination, and including but not limited to:

i. Trisomy 13 ii. Trisomy 18 iii. Hypoplastic Left Heart Syndrome iv. Omphalocele v. Gastroschesis vi. Holoprosencephaly
4. Known or suspected hepatic or renal insufficiency
5. Clinically uncontrolled seizures
6. Immunodeficiency other than due to prematurity
7. A history of standard immune globulin administration prior to first study drug infusion (excluding Hepatitis B Immune Globulin, HBIG)
8. Any history, in the infant subject or its mother, of a hypersensitivity or severe vasomotor reaction to immunoglobulin G, or blood products
9. Currently receiving, recently received, or planned to receive other investigational agents that could interfere with conduct or results of this study; including enrollment in another investigational study for a product under an IRB-approved protocol
10. Expectation that the patient will not be able to be followed for the duration of the study
11. Mother with serology positive for hepatitis B surface antigen

Minimum Eligible Age

48 Hours

Maximum Eligible Age

120 Hours

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes